Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protagonist Therapeutics Inc PTGX

Healthcare Biotechnology
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its... see more

Recent & Breaking News (NDAQ:PTGX)

Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study

PR Newswire August 1, 2019

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire July 16, 2019

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire June 18, 2019

Protagonist Therapeutics to Present at the BMO 2019 Prescription for Success Healthcare Conference

PR Newswire June 17, 2019

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire June 4, 2019

Protagonist Therapeutics Appoints Don Kalkofen as Chief Financial Officer

PR Newswire May 29, 2019

Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study

PR Newswire May 14, 2019

Protagonist Therapeutics Reports First Quarter 2019 Financial Results

PR Newswire May 8, 2019

Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists

PR Newswire May 8, 2019

Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019

PR Newswire May 7, 2019

Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9

PR Newswire April 1, 2019

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

PR Newswire March 12, 2019

Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results

PR Newswire March 5, 2019

Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28

PR Newswire February 21, 2019

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire January 16, 2019

Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia

PR Newswire January 9, 2019

Protagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and Pharmacology

PR Newswire January 7, 2019

Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943

PR Newswire December 13, 2018

Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

PR Newswire December 5, 2018

Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease

PR Newswire November 27, 2018